Acadian Asset Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Acadian Asset Management’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-109	Closed	-$49K	–	2102
2019 Q1	$49K	Sell	109 -1,154	-91%	-$505K	﹤0.01%	1682
2018 Q4	$577K	Buy	1,263 +762	+152%	+$472K	﹤0.01%	871
2018 Q3	$455K	Sell	501 -101	-17%	-$66.7K	﹤0.01%	909
2018 Q2	$353K	Buy	+602	New	+$393K	﹤0.01%	956

Other funds holding HTGM

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management's HTGM Position: Q2 2019 in Review

Acadian Asset Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2019, closing a stake of 109 shares — an estimated $49K sold.

Acadian Asset Management first reported a position in HTGM in Q2 2018 and held it in 4 quarters. The position peaked at $577K in Q4 2018. 43 funds tracked by Wall St. Rank hold HTGM as of Q2 2019.

Acadian Asset Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Acadian Asset Management sold 109 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2019, an estimated $49K.
Acadian Asset Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2018 and held it in 4 quarters.
Acadian Asset Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $577K in Q4 2018.
43 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2019.

Based on Acadian Asset Management's 13F filing for Q2 2019, filed 8 Aug 2019.